We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Harry Atkins MD

Harry Atkins MD

Associate Professor, Transplantation and Cell Therapy Program, The Ottawa Hospital and The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Harold Atkins, MD, is a physician of the Ottawa Hospital Transplantation and Cell Therapy Program, an Associate Professor of Medicine at the University of Ottawa, and a scientist in the Center for Innovative Cancer Research at the Ottawa Hospital Research Institute.

He received his Bachelor of Medical Science degree and Medical Degree from the University of Ottawa followed by a rotating internship year at the Victoria General Hospital in Victoria BC.  Specialty training in Internal Medicine was done at the University of Ottawa.   Clinical and research fellowships in Hematology, Stem Cell Transplantation and Experimental Hematology followed at the University of Washington and at the Ontario Cancer Institute. 

He specializes in hematopoietic stem cell transplantation and has spearheaded the use of stem cell transplantation for immune repair to treat patients with severe autoimmune diseases including multiple sclerosis, scleroderma, myasthenia gravis and others.  The outcome of a trial in Multiple Sclerosis was published in the Lancet in 2016.  He ran a clinical trial exploring the role of hematopoietic stem cell transplantation in preventing organ transplant rejection.  He is a member of a BiocanRx funded, pan-Canadian consortium to develop and improve the accessibility of new chimeric antigen receptor T lymphocytes for the treatment of hematological cancers.   He was awarded the OHRI’s Dr. Michel Chretien Researcher of the Year in 2016 and the Till and McCulloch Award from the Stem Cell Network in 2017.


Dr. Atkins has no relevant disclosures.